Elicio Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows (unaudited)
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(20,040) | $(21,770) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 82 | 106 |
| Amortization of right-of-use assets, operating leases | 490 | 453 |
| Non-cash interest expense | — | 219 |
| Amortization of debt discount | 128 | 35 |
| Change in fair value of warrant liabilities | (1,499) | 1,366 |
| Stock-based compensation | 1,803 | 1,227 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (1,257) | 1,387 |
| Other long-term prepaid assets | (55) | — |
| Accounts payable | 167 | 2,827 |
| Accrued expenses | 863 | (3,309) |
| Deferred research obligation | — | (1,169) |
| Operating lease liabilities | (492) | (441) |
| Net cash used in operating activities | (19,810) | (19,069) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs | 24,420 | 2,851 |
| Proceeds from the exercise of common warrants | — | 343 |
| Proceeds from issuance of common stock and common warrants from the January 2025 Offering, net of issuance costs | — | 9,143 |
| Proceeds from the June 2025 Promissory Note, net of issuance costs | — | 9,866 |
| Proceeds from the exercise of stock options | 117 | 57 |
| Net cash provided by financing activities | 24,537 | 22,260 |
| Effect of foreign currency on cash and cash equivalents | 1 | 105 |
| Net increase in cash and cash equivalents | 4,728 | 3,296 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 19,267 | 19,492 |
| Cash, cash equivalents, and restricted cash at the end of the period | $23,995 | $22,788 |
| Components of cash and cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $23,480 | $22,088 |
| Restricted cash | 515 | 700 |
| Total cash, cash equivalents and restricted cash | $23,995 | $22,788 |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Fair value of common stock warrants upon settlement | $— | $373 |
| Fair value of common warrants issued with January 2025 Offering | $— | $9,719 |
| Fair value of common warrants issued with June 2025 Promissory Note | $— | $641 |
| Conversion of Convertible Note and interest into equity | $— | $20,176 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.